Xueyong Lou

Xueyong Lou


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
YLYanfen Liu
Yanfen Liu
XLXueyong Lou
Xueyong Lou
Background: The rapid global spread of a new coronavirus disease known as COVID-19 has led to a significant increase in mortality rates, resulting in an unprecedented worldwide pandemic. Methods: The impact of COVID-19, particularly its long-term effects, has also had a profound effect on the health and well-being of individuals.Metabolic syndrome increases the risk of heart and brain diseases, presenting a significant danger to human well-being. Purpose: The prognosis of long COVID and the progression of metabolic syndrome interact with each other, but there is currently a lack of systematic reports.In this paper, the pathogenesis, related treatment and prognosis of long COVID and metabolic syndrome are systematically reviewed.

7 August 2024 in DNA and Cell Biology
Verified
Journal Article
Closed access
YLYanfen Liu
Yanfen Liu
DNDongying Nie
Dongying Nie
XLXueyong Lou
Xueyong Lou
Coronary artery disease (CAD) is associated with a high fatality rate and a heavy global health care burden. Glucagon-like peptide-1 (GLP-1) exerts positive cardiovascular effects, although the molecular mechanisms are unclear. Therefore, this study aimed to verify whether the cardioprotective effects of GLP-1 are mediated through the regulation of micro-RNA (miRNA) expression. Follow-up assessments were conducted for 116 patients with type 2 diabetes mellitus (T2DM) alone (controls) and 123 patients with both T2DM and CAD. After matching, each group comprised 63 patients, and age, body mass index, and serum levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglycerides (TG), and hemoglobin A1C (HbA1c) were compared. Subsequently, the expression profiles of four circulating miRNAs (miR-203a-3p, miR-429, miR-205-5p, and miR-203b-5p) were assessed via quantitative reverse transcription real-time polymerase chain reaction in the 63 patients with diabetes and CAD between 6 months (baseline) and 12 months after the initiation of GLP-1 receptor (GLP-1R) therapy. As expected, the metabolic factors were significantly improved after 6 months of treatment with GLP-1R compared with pre-treatment values, and the expression levels of two of the miRNAs (miR-203a-3p and miR-429) decreased from baseline levels in those with diabetes and CAD. The results suggest that the cardiovascular benefits induced by GLP-1R are mediated via suppressed expression of two miRNAs: miR-203a-3p and miR-429.

20 December 2023 in Research Square
Verified
Preprint
Open access
PDF file
XLXueyong Lou
Xueyong Lou
DNDongying Nie
Dongying Nie
XLXueyong Lou
Xueyong Lou
Purpose Coronary artery disease (CAD) is associated with a high fatality rate and a heavy global health care burden. Glucagon-like peptide-1 (GLP-1) exerts positive cardiovascular effects, although the molecular mechanisms are unclear. Therefore, this study aimed to verify whether the cardioprotective effects of GLP-1 are mediated through the regulation of micro-RNA (miRNA) expression. Materials and Methods Follow-up assessments were conducted for 116 patients with type 2 diabetes alone (controls) and 123 patients with both type 2 diabetes and CAD. After matching, each group comprised 63 patients, and age, body mass index, and serum levels of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and haemoglobin A1C were compared. Subsequently, the expression profiles of four circulating miRNAs (miR-203a-3p, miR-429, miR-205-5p, and miR-203b-5p) were assessed via qRT-PCR in the 63 patients with diabetes and CAD between six months (baseline) and twelve months after the initiation of GLP-1 therapy. Results As expected, the metabolic factors were significantly improved after 6 months of treatment with GLP-1 compared with pre-treatment values, and the expression levels of two of the miRNAs (miR-203a-3p and miR-429) decreased from baseline levels in those with diabetes and CAD. Conclusions The results suggest that the cardiovascular benefits induced by GLP-1 are mediated via suppressed expression of two miRNAs: miR-203a-3p and miR-429.

23 January 2026 in Medicine
Verified
Journal Article
Open access
YLYanfen Liu
Yanfen Liu
JLJun Liu
Jun Liu
XLXueyong Lou
Xueyong Lou
Rationale: The systemic consequences of hypoglycemic brain injury beyond the central nervous system remain poorly understood. While the brain-gut axis is a pivotal communication network, clinical evidence linking hypoglycemia to gut dysmotility is confounded by comorbidities like autonomic neuropathy. This case report aims to present the first documented evidence of isolated hypoglycemic brain injury inducing transient, profound diarrhea through a hypothesized brain-gut pathway, in a patient with all confounding factors rigorously excluded and premorbid normal gut histology. Patient concerns: A 65-year-old male with type 2 diabetes suffered an insulin overdose, resulting in profound hypoglycemia (glucose 1.8 mmol/L) and a 10-minute comatose state. Twenty-four hours post-hypoglycemia, he developed acute-onset, large-volume watery diarrhea (3–4 episodes daily). Diagnoses: A comprehensive diagnostic workup excluded all common infectious, inflammatory, autoimmune, metabolic, and structural causes. Interventions: The diarrhea proved refractory to a sequential therapeutic regimen including loperamide, smectite, Saccharomyces boulardii, and cholestyramine. Outcomes: The symptoms persisted unabated until their abrupt and complete resolution on day 11, without therapeutic intervention. At 3-month follow-up, the patient remained asymptomatic with normal bowel function and objective tests. Lessons: This case illuminates a novel, self-limiting cerebro-enteral pathway activated by hypoglycemia, which we hypothesize is mediated by blood–brain barrier-disruption and corticotropin-releasing hormone-driven neurohumoral cascades. It underscores the need to consider central nervous system injury in the differential diagnosis of unexplained acute diarrhea and highlights the necessity for monitoring gastrointestinal symptoms post-hypoglycemia.

1 October 2025 in Journal of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
YLYan Fen Liu
Yan Fen Liu
XLXueyong Lou
Xueyong Lou
Thyroid disorders, including hypothyroidism, hyperthyroidism, thyroid cancer, and nodular disease, represent a substantial global health burden. Current therapeutic options are often inadequate, frequently necessitating lifelong hormone replacement or causing irreversible tissue damage. Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic platform due to their dual capacity to differentiate into thyroid-like cells and modulate immune dysregulation. This review provides a critical examination of preclinical evidence supporting MSC-based interventions for thyroid disorders. We analyzed studies demonstrating MSC potential in restoring thyroid hormone production via thyrocyte regeneration, rebalancing T-helper 17 (Th17)/regulatory T cell (Treg) cell ratios in autoimmune thyroiditis, and inhibiting tumor progression through paracrine mechanisms. Key challenges, such as tumorigenesis risk from MSC-tumor interactions, source variability, regulatory complexities for standardization, and unresolved issues in differentiation protocols and safety biomarkers, are systematically evaluated. The primary purpose of this review was to assess the therapeutic potential and limitations of MSC-based strategies for treating thyroid disorders. The review emphasizes the critical need for the development of robust translational frameworks that address existing obstacles, including the refinement of differentiation protocols, establishment of safety biomarkers, and exploration of engineered MSC-derived extracellular vesicles with targeted therapies, to bridge the gap between preclinical promise and clinical application.